

A blue horizontal banner with an orange circle on the left side, containing the text 'PRESS RELEASE' in white capital letters.

PRESS RELEASE

Sosei Heptares announces nomination of new disease target by Takeda under strategic multi-target research, development and commercialization partnership

- *Sosei Heptares receives undisclosed milestone payment from Takeda as collaborative progress continues to be made*

Tokyo, Japan and Cambridge, UK, 8 February 2022 – Sosei Group Corporation (“the Company”; TSE: 4565), the world leader in G protein-coupled receptor (GPCR) focused structure-based drug design (SBDD) and development, has been notified by its partner Takeda Pharmaceutical Company Limited (“Takeda”) that a new disease target has been nominated under their ongoing 2019 partnership agreement. Sosei Heptares will receive an undisclosed payment from Takeda for achieving this milestone.

The multi-target research, development and commercialization partnership between the companies is making good progress with early research milestones being met through the powerful combination of Sosei Heptares’ proprietary GPCR-focused structure-based drug design capabilities with Takeda’s extensive discovery, development and therapeutic area expertise. The partnership is directed towards the discovery of novel therapeutic agents against multiple GPCR targets nominated by Takeda, with an initial focus on gastro-intestinal diseases.

Shinichi Tamura, President and CEO of Sosei Heptares, commented “We are delighted to announce the achievement of this milestone from our ongoing partnership with Takeda. The collaboration has been very productive thus far, with a strong working relationship being established and multiple early milestones being reached. I look forward to seeing further progress from this partnership as we look to deliver new medicines for gastro-intestinal diseases.”

As per the agreement, Takeda is responsible for developing and commercializing potential new medicines for each novel target and will have exclusive global rights to these agents. Sosei Heptares has received upfront and multiple early research milestone payments, and is eligible to receive additional future development, commercialization and net sales-based payments that may exceed \$1.2 billion. Sosei Heptares is also eligible to receive tiered royalties on net sales of any licensed products by Takeda resulting from the partnership.

-ENDS-

PRESS RELEASE

About Sosei Heptares

We are an international biopharmaceutical group focused on the discovery and early development of new medicines originating from our proprietary GPCR-targeted StaR[®] technology and structure-based drug design platform capabilities. We are advancing a broad and deep pipeline of novel medicines across multiple therapeutic areas, including neurology, immunology, gastroenterology and inflammatory diseases.

We have established partnerships with some of the world's leading pharmaceutical companies and multiple emerging technology companies, including AbbVie, AstraZeneca, Biohaven, Genentech (Roche), GSK, Neurocrine Biosciences, Novartis, Pfizer, Takeda and Verily. Sosei Heptares is headquartered in Tokyo, Japan with corporate and R&D facilities in Cambridge, UK.

"Sosei Heptares" is the corporate brand and trademark of Sosei Group Corporation, which is listed on the Tokyo Stock Exchange (ticker: 4565). Sosei, Heptares, the logo and StaR[®] are trademarks of Sosei Group companies.

For more information, please visit <https://soseiheptares.com/>
LinkedIn: [@soseiheptaresco](#) | Twitter: [@soseiheptaresco](#) | YouTube: [@soseiheptaresco](#)

Enquiries

Sosei Heptares – Media and Investor Relations

Hironoshin Nomura, SVP Investor Relations and Corporate Strategy
+81 (0)3 6679 2178 | Hironoshin.Nomura@SoseiHeptares.com

Shinichiro Nishishita, VP Investor Relations, Head of Regulatory Disclosures
+81 (0)3 5210 3399 | IR@SoseiHeptares.com

Citigate Dewe Rogerson (for Japanese Media)

Yas Fukuda
+81 (0)3 4360 9234, Yas.Fukuda@citigatedewerogerson.com

MEDI STRAVA Consulting (for International Media)

Mark Swallow, David Dible, Eleanor Perkin
+44 (0)203 928 6900, SoseiHeptares@medistrava.com

Forward-looking statements

This release contains forward-looking statements, including statements about the discovery, development and commercialization of products. Various risks may cause Sosei Group Corporation's actual results to differ materially from those expressed or implied by the forward-looking statements, including: adverse results in clinical development programs; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialize products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to

A blue horizontal bar with rounded ends containing the text 'PRESS RELEASE' in white capital letters.

PRESS RELEASE

conduct research and development and to expand commercialization activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.